Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus TIOTROPIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus TIOTROPIUM BROMIDE.
CANTIL vs TIOTROPIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Tiotropium bromide is a long-acting, competitive, and reversible muscarinic receptor antagonist (anticholinergic). It binds preferentially to M3 receptors in the smooth muscle of the bronchi, inhibiting acetylcholine-mediated bronchoconstriction and mucus secretion, leading to prolonged bronchodilation.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
Inhalation (oral): 18 mcg once daily via HandiHaler; or 2.5 mcg (2 puffs) once daily via Respimat inhaler.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
Terminal elimination half-life: 5–6 days (inhalation). Longer half-life allows once-daily dosing. Steady-state reached in 2–3 weeks.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Primarily renal: 14% of dose excreted unchanged in urine; remainder as inactive metabolites via biliary/fecal (70%) and renal (30% total).
Category C
Category A/B
Anticholinergic / Antispasmodic
Anticholinergic